Where does Syndax Pharmaceuticals's income statement data come from?

Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$217.42M+397%	$172.6M+629%	$111.55M+597%	$78.18M+2,134%	$43.72M—
Research and development	$255.99M+3.7%	$258.78M+7.1%	$245.67M+6.2%	$260.36M+30.6%	$246.79M+33.1%
Selling, general and administrative	——	$179.68M+48.6%	$164.98M+53.6%	$150.28M+60.0%	$135.58M+68.6%
General and administrative	——	——	——	——	——
Compensation and benefits	——	——	——	——	——
Depreciation and amortization	——	——	——	——	——
Other operating expenses	$440.95M+13.8%	$445.68M+22.7%	$418.45M+24.1%	$417.23M+43.1%	$387.64M+47.1%
Total operating expenses	$440.95M+13.8%	$445.68M+22.7%	$418.45M+24.1%	$417.23M+43.1%	$387.64M+47.1%
Operating income	-$223.53M+35.0%	-$273.08M+19.6%	-$306.9M+4.5%	-$339.05M-17.7%	-$343.92M-30.5%
Operating margin	-102.8%+684pp	-158.2%+1,276pp	-275.1%+1,732pp	-433.7%+7,795pp	-786.6%—
Interest expense	$4K+107%	$6K+700%	-$118K-163%	-$95K-141%	-$54K-124%
Interest income	$19.11M-26.6%	$22.73M-12.9%	$25.51M+4.0%	$25.68M+5.1%	$26.02M+11.5%
Other income (expense), net	-$19.72M-255%	-$12.34M-159%	-$4.68M-119%	$4.06M-83.0%	$12.71M-44.3%
Net investment gains (losses)	——	——	——	——	——
Income tax expense	——	——	——	——	——
Net income	-$243.25M+26.6%	-$285.42M+10.5%	-$311.58M-4.9%	-$334.99M-26.8%	-$331.2M-37.6%
Net margin	-111.9%+646pp	-165.4%+1,181pp	-279.3%+1,577pp	-428.5%+7,117pp	-757.5%—
Diluted earnings per share	-$2.79+27.5%	-$3.29+11.6%	-$3.60+1.1%	-$3.88-14.5%	-$3.85-19.2%
Basic earnings per share	-$2.79+27.5%	-$3.29+11.6%	-$3.60+1.1%	-$3.88-14.5%	-$3.85-19.2%
Weighted-average shares, diluted	347.8M+1.6%	345.8M+1.2%	344.8M+5.7%	343.6M+10.6%	342.5M+16.1%
Weighted-average shares, basic	347.8M+1.6%	345.8M+1.2%	344.8M+5.7%	343.6M+10.6%	342.5M+16.1%
Litigation provision	——	——	——	——	——
Royalty expense	$37.58M+190%	$33.78M+585%	$29.12M—	$20.83M—	$12.98M—
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Share-based compensation expense related to employee stock plans	——	——	——	——	——
Pre-tax stock-based compensation cost	——	——	——	——	——
Amortization Of Financing Costs	$173K+21.8%	$229K+663%	$259K—	$197K—	$142K—
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	——
Cost Of Product Sales	$8.72M+410%	$6.97M+744%	$5.09M—	$2.99M—	$1.71M—
Total net securities (losses)	——	——	——	——	——
Defined contribution plan costs	——	——	——	——	——
Depreciation	——	——	——	——	——
Depreciation And Related Adjustment	——	——	——	——	——
Employee Withholdings Espp	——	——	——	——	——
Accounts payable	——	——	——	$5.79M—	$1.24M—
Increase (Decrease) in Accounts Receivable	$22.15M+40.9%	$30.39M+300%	$25.4M—	$19.45M—	$15.72M—
Increase (Decrease) in Accounts Receivable and Other Operating Assets	——	——	——	——	——
Increase in accrued expenses and other liabilities	$16.35M-29.9%	$42.17M+120%	$28.13M+87.7%	$48.06M+493%	$23.32M+34.5%
Increase Decrease In Collaboration Receivable	——	——	——	——	——
Increase (Decrease) in Inventories	$29.96M+557%	$32.09M+8,668%	$24.66M—	$17.47M—	$4.56M—
Increase (Decrease) in Prepaid Expense and Other Assets	$12.7M—	$14.54M—	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$20.66M-94.1%	$13.68M-96.1%	$355.18M+34.3%	$352M+33.8%	$352.13M+33.5%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	$234.28M—	$290.04M—	-$60.52M—	-$46.1M—	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$278.16M+2.9%	-$322.98M-17.5%	-$310.88M-20.1%	-$302.67M-25.5%	-$286.52M-39.8%
Net Sales	——	——	——	——	——
Noncash Operating Lease Expense	——	——	——	——	——
Number Of Reportable Segments Disclosed By Definition Flag	——	——	——	——	——
Other comprehensive income/(loss)	——	——	——	——	——
Net unrealized gains (losses) on securities still held	——	——	——	——	——
Other income, net (Note 6)	-$1.25M-228%	-$1.28M-419%	-$1.19M-506%	-$881K-200%	-$381K-26.6%
Payments to Acquire Short-Term Investments	$224.66M-43.9%	$195.81M-64.8%	$509.01M+64.2%	$491.92M+29.7%	$400.21M-13.1%
Proceeds from sales and redemptions of investments in debt securities classified as available for sale	$459.13M+22.8%	$486.03M+44.1%	$448.62M+30.8%	$445.82M+22.0%	$373.97M-18.5%
Cash received from option exercises	$19.21M+194%	$12.14M+51.7%	$9.97M+100%	$6.17M+54.2%	$6.53M+38.6%
Proceeds from issuance of common stock relating to employee stock plans	$1.53M-21.5%	$1.62M-5.7%	$1.65M+21.3%	$2.18M+102%	$1.95M+90.7%
Revenue From Contract With Customer Excluding Assessed Tax	$217.42M+397%	$172.6M+629%	$111.55M+597%	$78.18M+2,134%	$43.72M—
Stock-based compensation	$49.18M+10.5%	$47.5M+10.4%	$48.55M+24.3%	$48.4M+36.6%	$44.51M+32.4%
Stock Issued During Period, Value, Stock Options Exercised	——	——	——	——	——
EBIT	-$223.53M+35.0%	-$273.08M+19.6%	-$306.9M+4.5%	-$339.05M-17.7%	-$343.92M-30.5%
EBITDA	——	——	——	——	——
EBIT	-$223.53M+35.0%	-$273.08M+19.6%	-$306.9M+4.5%	-$339.05M-17.7%	-$343.92M-30.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Syndax Pharmaceuticals's income statement data come from?: Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.